62
edits
Changes
→References
==References==
==References==
*Aubol, B.E., Wu, G., Keshwani, M.M., Movassat, M., Fattet, L., Hertel, K.J., Fu, X.-D., and Adams, J.A. (2016). Release of SR Proteins from CLK1 by SRPK1: A Symbiotic Kinase System for Phosphorylation Control of Pre-mRNA Splicing. Mol. Cell 63, 218–228. PMID: 27397683
*Cáceres, J.F., Screaton, G.R., and Krainer, A.R. (1998). A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev. 12, 55–66. PMID: 9420331
*Ding, J.H., Xu, X., Yang, D., Chu, P.H., Dalton, N.D., Ye, Z., Yeakley, J.M., Cheng, H., Xiao, R.-P., Ross, J., et al. (2004). Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. EMBO J. 23, 885–896. PMID: 14963485
*Edmond, V., Moysan, E., Khochbin, S., Matthias, P., Brambilla, C., Brambilla, E., Gazzeri, S., and Eymin, B. (2011). Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 30, 510–523. PMID: 21157427
*Erkelenz, S., Mueller, W.F., Evans, M.S., Busch, A., Schöneweis, K., Hertel, K.J., and Schaal, H. (2013). Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. RNA N. Y. N 19, 96–102. PMID: 23175589
*Fu, X.D., and Ares, M. (2014). Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 15, 689–701. PMID: 25112293
*Fu, X.D., and Maniatis, T. (1990). Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus. Nature 343, 437–441. PMID: 2137203
*Fu, X.D., and Maniatis, T. (1992). The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3’ splice site. Proc. Natl. Acad. Sci. U. S. A. 89, 1725–1729. PMID: 1531875
*Han, J., Ding, J.H., Byeon, C.W., Kim, J.H., Hertel, K.J., Jeong, S., and Fu, X.-D. (2011). SR proteins induce alternative exon skipping through their activities on the flanking constitutive exons. Mol. Cell. Biol. 31, 793–802. PMID: 21135118
*Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., et al. (2013). Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. J. Clin. Oncol. 31, 2428–2436. PMID: 23690417
*Kar, S.A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M., Guinta, K., et al. (2013). Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 98, 107–113. PMID: 22773603
*Kim, E., Ilagan, J.O., Liang, Y., Daubner, G.M., Lee, S.C.W., Ramakrishnan, A., Li, Y., Chung, Y.R., Micol, J.-B., Murphy, M., et al. (2015). SRSF2 Mutations Contribute to Myelodysplasia Through Mutant-Specific Effects on Exon Recognition. Cancer Cell 27, 617–630. PMID: 25965569
*Komeno, Y., Huang, Y.J., Qiu, J., Lin, L., Xu, Y., Zhou, Y., Chen, L., Monterroza, D.D., Li, H., DeKelver, R.C., et al. (2015). SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing. Mol. Cell. Biol. 35, 3071–3082. PMID: 26124281
*Lareau, L.F., Inada, M., Green, R.E., Wengrod, J.C., and Brenner, S.E. (2007). Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 446, 926–929. PMID: 17361132
*Lin, S., and Fu, X.D. (2007). SR proteins and related factors in alternative splicing. Adv. Exp. Med. Biol. 623, 107–122. PMID: 18380343
*Lin, S., Coutinho-Mansfield, G., Wang, D., Pandit, S., and Fu, X.-D. (2008). The splicing factor SC35 has an active role in transcriptional elongation. Nat. Struct. Mol. Biol. 15, 819–826. PMID: 18641664
*Liu, H.X., Chew, S.L., Cartegni, L., Zhang, M.Q., and Krainer, A.R. (2000). Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell. Biol. 20, 1063–1071. PMID: 10629063
*Mason, C.C., Khorashad, J.S., Tantravahi, S.K., Kelley, T.W., Zabriskie, M.S., Yan, D., Pomicter, A.D., Reynolds, K.R., Eiring, A.M., Kronenberg, Z., et al. (2016). Age-related mutations and chronic myelomonocytic leukemia. Leukemia 30, 906–913. PMID: 26648538
*McKerrell, T., Park, N., Moreno, T., Grove, C.S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M.A., Hodkinson, C., et al. (2015). Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis. Cell Rep. 10, 1239–1245. PMID: 25732814
*Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., et al. (2012). SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120, 3080–3088. PMID: 22919025
*Merdzhanova, G., Gout, S., Keramidas, M., Edmond, V., Coll, J.-L., Brambilla, C., Brambilla, E., Gazzeri, S., and Eymin, B. (2010). The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 29, 5392–5403. PMID: 20639906
*Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Loo, P.V., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., et al. (2013). Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627. PMID: 24030381
*Roscigno, R.F., and Garcia-Blanco, M.A. (1995). SR proteins escort the U4/U6.U5 tri-snRNP to the spliceosome. RNA N. Y. N 1, 692–706. PMID: 7585254
*Thol, F., Kade, S., Schlarmann, C., Löffeld, P., Morgan, M., Krauter, J., Wlodarski, M.W., Kölking, B., Wichmann, M., Görlich, K., et al. (2012). Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119, 3578–3584. PMID: 22389253
*Wang, H.Y., Xu, X., Ding, J.H., Bermingham, J.R., and Fu, X.D. (2001). SC35 plays a role in T cell development and alternative splicing of CD45. Mol. Cell 7, 331–342. PMID: 11239462
*Xiao, R., Sun, Y., Ding, J.-H., Lin, S., Rose, D.W., Rosenfeld, M.G., Fu, X.-D., and Li, X. (2007). Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis. Mol. Cell. Biol. 27, 5393–5402. PMID: 17526736
*Yang, J., Yao, D., Ma, J., Yang, L., Guo, H., Wen, X., Xiao, G., Qian, Z., Lin, J., and Qian, J. (2016). The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. Tumor Biol. 37, 10107–10114. PMID: 26820131
*Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011). Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69. PMID: 21909114
*Zahler, A.M., Neugebauer, K.M., Lane, W.S., and Roth, M.B. (1993). Distinct functions of SR proteins in alternative pre-mRNA splicing. Science 260, 219–222. PMID: 8385799
*Zhang, J., Lieu, Y.K., Ali, A.M., Penson, A., Reggio, K.S., Rabadan, R., Raza, A., Mukherjee, S., and Manley, J.L. (2015). Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc. Natl. Acad. Sci. U. S. A. 112, E4726–E4734. PMID: 26261309
*Zhou, Z., and Fu, X.D. (2013). Regulation of Splicing by SR proteins and SR Protein-Specific Kinases. Chromosoma 122, 191–207. PMID: 23525660
*Zhou, Z., Qiu, J., Liu, W., Zhou, Y., Plocinik, R.M., Li, H., Hu, Q., Ghosh, G., Adams, J.A., Rosenfeld, M.G., et al. (2012). The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol. Cell 47, 422–433. PMID: 22727668
== Notes ==
== Notes ==